Multiple Sclerosis (MS) is believed to be a disease that affects people in their 30s-40s. However, pediatric cases have been reported and account for approximately 5% of all MS cases (Yeh et al 2009). Early diagnosis of MS is fundamental for effective treatment and positive disease prognosis. Establishing that this disease is manifested at an early age is critical since there is currently no disease modifying therapy (DMT) approved for pediatric cases. Recent pediatric clinical trials show that there is a growing awareness of pediatric data. Consciousness can diminish misdiagnosis of MS in pediatric patients. Conditions such as acute disseminated encephalomyelitis (ADEM) and subacute combined degeneration can be commonly confused with this disease due to similar signs and symptoms. This study aims to estimate the prevalence of Hispanic patients whose symptom onset began at or before the age of 18. Data provided by Puerto Rico (PR) MS Registry was collected from self-reported questionnaires. Descriptive statistics were performed to analyze data set. PRMS Registry has 2904 enrolled patients out of which 1638 had the data required for use in this study. 173 (10.6%) of patients analyzed experienced their first symptom on or before the age of 18. Out of those 25 (14.5%) were under the age of 13 and 148 (85.5%) were between the ages of 13-18. 132 (76.3%) of the patients were female and 40 (30.3%) were male, sustaining that 3:1 ratio seen in MS. This study shows that 10.6% of patients diagnosed with MS in PR experienced their first symptom on or before the age of 18, demonstrating that disease onset can start much earlier than previously expected. Understanding this fact will diminish misdiagnosis and allow for better treatment of these patients.

Estimate the prevalence of Hispanic patients whose symptom onset began at or before the age of 18.

Acknowledgments: We would like to thank the PRMS Foundation and the collaborative group GEPREM for their aid in this investigation. Disclosure: Dr. China is a speaker for Novartis, Biogen, Teva, and Genzyme. None of the authors of this research received any grants or monetary compensation.